Fintel reports that on January 10, 2025, BTIG initiated coverage of ImmunityBio (NasdaqGS:IBRX) with a Buy recommendation.

We recently published a list of 10 Firms Close Shortened Trading Week Higher. In this article, we are going to take a look at ...

Energy & Infrastructure Analyst Lewis and Fixed Income Strategist Malley discuss bitcoin mining trends and themes across the capital ...

FiscalNote Holdings Inc (NOTE) stock saw a decline, ending the day at $1.17 which represents a decrease of $-0.16 or -12.03% from the prior close of $1.33. The stock opened at $1.28 and touched a low ...

BTIG analyst Justin Zelin lowered the firm’s price target on Jasper Therapeutics (JSPR) to $64 from $90 and keeps a Buy rating on the shares ...

BTIG Research has recently reduced Fiverr International Ltd (FVRR) stock to Neutral rating, as announced on November 4, 2024, according to Finviz. Earlier, on July 2, 2024, UBS had reduced the stock ...

The S&P 500's rally of 1.8% over just the last two sessions is nice, "but not a game changer yet," according to BTIG's technical guru, Jonathan Krinsky. The chart he provides, below, shows the stock ...

Last week, BTIG analyst Jake Fuller reiterated a Buy rating on Uber Technologies (UBER) stock with a price target of $90. The analyst remains bullish on the ride-hailing company but expects its Q4 ...

Here are four large-cap value stocks that growth and income investors may want to consider now. History suggests they could rally this year.

BTIG raised the firm’s price target on Glaukos (GKOS) to $157 from $149 and keeps a Buy rating on the shares as part of a broader research note updating the firm’s models on Medical Technology names ...

BTIG's Krinsky noted that while equity markets in the first half of 2024 were fueled mostly by the surge in mega-cap names ...

According to a BTIG strategist, the rally in the index was rejected from the previous support trendline and even though there are still four days left for the Santa Claus rally to deliver gains, there ...